Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance

Amgen, Inc.Trade
ProShares UltraPro Short QQQ ETFTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs ProShares UltraPro Short QQQ ETF — how do they compare? Amgen, Inc. trades at $417.26 (market cap $224.14B), while ProShares UltraPro Short QQQ ETF trades at $37.34. The key difference: Amgen, Inc. pays a 2.43% dividend while ProShares UltraPro Short QQQ ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.

AMGNSQQQ
Market Cap
$224.14B
Sector
HealthLeveraged / Inverse
52-Week High
$417.20$92.95
52-Week Low
$271.18$36.31
Enterprise Value
$267.45B
Dividend Yield
2.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.

Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.

ProShares UltraPro Short QQQ ETF

SQQQ trades at $37.05, down 1.83% on the day, reflecting its inverse leveraged structure designed to move opposite the Nasdaq-100. The technical picture remains bearish with moving averages signaling continued downward pressure, though oversold conditions suggest potential for short-term bounces. Recent news highlights SQQQ's role as a tactical hedging tool rather than a long-term investment, with significant erosion risk due to daily reset mechanisms.

SQQQ serves as a high-risk tactical instrument for bearish Nasdaq-100 bets, with success dependent on precise market timing. The ETF faces structural decay from daily rebalancing, making it unsuitable for buy-and-hold strategies. Current market volatility and tech sector concerns create potential short-term opportunities, but long-term holders have historically suffered substantial losses.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About ProShares UltraPro Short QQQ ETF

SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.

Read more on SQQQ